TBPH - Theravance Biopharma, Inc.
IEX Last Trade
9.86
1.585 16.075%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:56 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$8.28
1.59
19.15%
Fundamental analysis
23%
Profitability
15%
Dept financing
17%
Liquidity
75%
Performance
20%
Performance
5 Days
2.71%
1 Month
4.01%
3 Months
23.74%
6 Months
17.26%
1 Year
-10.78%
2 Year
-12.83%
Key data
Stock price
$9.86
DAY RANGE
$8.28 - $9.72
52 WEEK RANGE
$7.76 - $11.71
52 WEEK CHANGE
-$13.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Rick E. Winningham
Region: US
Website: theravance.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: theravance.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.
Recent news